![]() |
Some tea, possibly Darjeeling, yesterday
|
![]() |
Registered EUTM
|
![]() |
Form of use -
Alex believes this is meant
to represent a Saguaro cactus,
although expert confirmation
would be welcome
|
Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, info-tech, privacy and confidentiality issues from a mainly UK and European perspective. The team is Eleonora Rosati, Annsley Merelle Ward, Neil J. Wilkof, and Merpel. Nicola Searle is currently on sabbatical. Read, post comments and participate! E-mail the Kats here
![]() |
Some tea, possibly Darjeeling, yesterday
|
![]() |
Registered EUTM
|
![]() |
Form of use -
Alex believes this is meant
to represent a Saguaro cactus,
although expert confirmation
would be welcome
|
![]() |
The AmeriKat is no longer in the dark about what the Dutch Supreme Court were saying in MSD v Teva |
"Extent of protection of Swiss-type claims
Direct infringement
3.4.4 The difficulty arises with a patent containing a Swiss-type claim, which is formulated by its nature as a process claim (see 3.4.2), since as a result of the effect of Article 64(2) EPC or section 53(1) preamble and at b DPA 1995 (cf. above in 3.4.2), the extent of protection would also extend to the manufacture or application of the substance for the first medical indication if that patent has expired. This would be incompatible with the principle underlying patent law to the effect that anyone is at liberty to apply the doctrine of a patent that is no longer in effect, and also with the principle expressed in Article 69 EPC that the extent of protection of a patent should not extend beyond what is justified by the invention. For this reason, it must be assumed that a manufacturer or seller will only then directly infringe a patent with a Swiss-type claim if he foresees or ought to foresee that the generic substance he manufacturers or offers will intentionally be used for treatment covered by the second medical indication patent. This requires that the average person skilled in the art, on the basis of the SmPC and/or the product information leaflet or some other circumstance, will consider that the substance is (also) intended for or suited to that treatment. The manufacturer or seller will then have to take all effective measures that can reasonably be required of him to prevent his product from being dispensed for the patented second medical indication. The mere circumstance of a carve-out in the SmPC and product information leaflet of the generic drug – as in the present case – is generally not sufficient to rule out direct infringement. (Cf. Supreme Court 14 April 2017, ECLI:NL:HR:2017:692, NJ 2017/296, para. 3.5.2).
3.5 Against the background of all of the foregoing factors, cassation grounds 1.1, 1.2 and 1.3 correctly complain that the distinction drawn by the Appellate Court in the scope of protection of patents for the 'classic second medical indication' and the 'sub-group indication', mentioned at 4.2 of the contested judgment, is an incorrect distinction. As follows from the deliberations at 3.4.4 above, it is necessary in all cases of Swiss-type claims for (direct) infringement, and also sufficient, that the average person skilled in the art will consider that the substance is (also) intended for or suited to the treatment covered by the second medical indication patent, that the manufacturer or seller foresees or ought to foresee that the generic drug he manufactures or offers will intentionally be used for that treatment and that he does not take the steps specified above in 3.4.4. There is no place in the system of the EPC for a categorical distinction between the two types of second medical indications, introduced in abstracto, as done by the Appellate Court at the end of 4.4 – in relation to the specifically indicated use. The remaining complaints in cassation ground 1 require no discussion. The same applies to cassation ground 2.
Indirect infringement
. . . .
3.6.3 As already held at 3.4.2 above, Swiss-type claims are recognized in order to be able to protect a second medical indication as a patent and they take the form of purpose-limited process claims. It could be argued that, taken literally, there cannot be an indirect infringement of such a patent, for instance by an intermediary, since he would after all not be supplying or offering to supply means that could be used for the process in the manner specified in section 73(1) DPA 1995, consisting of the use of the substance mentioned in the claim for the preparation of a pharmaceutical product. Against the background of the reason that gave rise to recognition of the Swiss-type claims, and also having regard to the possibility available in the EPC since the revision in 2000 of linking a product-bound result claim to a patent for the protection of a second medical indication (Article 54(5) EPC incorporated in the DPA 1995 as Section 4(6)) – a revision that did not intend to break with the patentability of substances or combinations, as developed in case law, by means of a Swiss type claim (see EBoA 19 February 2010, G 0002/08, at 5.10.1-4 and the Preparatory Documents MR/18/00 and MR/24/00 quoted therein) – the reasonable protection of the patent proprietor prescribed by Article 1 of the Protocol justifies accepting that there can be an indirect infringement of a Swiss-type claim, on the same basis as for a claim in accordance with the current Article 54(5) EPC. A finding along the same lines was made by the Bundesgerichtshof (BGH 14 June 2016, no. X ZR 29/15, GRUR 2016/921 (Eli Lilly v Actavis), paras. 83-85). The possibility of an indirect infringement of a Swiss-type claim has also been acknowledged by the Supreme Court of the United Kingdom (UKSC 12 July 2017, no. [2017] UKSC 48 (Actavis v Eli Lilly), paras. 103-112).The AmeriKat was specifically struck by this comment at para 3.6.3:
3.6.4 This means that, as is the case with a patent containing a claim such as those rendered possible by Article 54(5) EPC, an indirect infringement of a Swiss-type claim is possible. With a purpose-limited product claim, the purpose given to the product (the drug) is after all "an essential element of the invention" as specified in section 73 DPA 1995. The foregoing deliberations mean that the manufacturer of a generic medicine can also indirectly infringe a patent for a second medical indication, namely if he supplies or offers to supply the drug to persons not entitled to work the invention and where he knows or it is obvious given the circumstances, that the drug is suitable and intended for the patented second medical indication. It is not an objection to this that he can therefore both directly and indirectly infringe such a patent. The UKSC has also held, as is apparent from the case law cited at 3.6.3, that the same conduct may amount to both direct and indirect infringement."
"The possibility of an indirect infringement of a Swiss-type claim has also been acknowledged by the Supreme Court of the United Kingdom (UKSC 12 July 2017, no. [2017] UKSC 48 (Actavis v Eli Lilly), paras. 103-112)."So it seems, the Actavis v Lilly ripple effect (although on a different point) is definitely being felt far and wide, including in the Dutch Supreme Court.
"The Brand Authenticity conference breaks new ground for INTA - it is the first INTA conference dealing with what is an increasingly important topic for brands and consumers alike. Consumers are taking more of an interest in the ethical and sustainable credentials of brands and, in turn, companies are waking up to the risks and rewards in this area. Brand professionals can add value by understanding this developing environment, the legal tools available to brands to earn and retain consumer trust and loyalty, and how best to deploy these tools.
Santiago Peralta, co-founder of Pacari Chocolate, kicked off proceedings with a passionate keynote address. Based in Quito, Ecuador, Pacari is a pioneering independent "tree to bar" chocolate manufacturer. Santiago explained how this model ensures quality and fairness at every stage of the process. Pacari is the most-awarded chocolate ever at the World Chocolate Awards (the "Olympics of chocolate") and, based on the gratefully-received samples, the author can see why. Santiago spoke about how the values of sustainability (over all timescales) and responsibility for the welfare of suppliers and employees are central to the company's identity. Pacari has received various certifications, such as the biodynamic Demeter and USDA Organic marks, and as a B Corp. Clearly, these certifications are hugely valued by Pacari - they serve the dual purpose of confirming that the company is living up to its ethical principles, and also serve as a badge of assurance to Pacari's target customers. Next was a series of presentations covering the evolution of corporate social responsibility (CSR).
Frederick Mostert of the Oxford Intellectual Property Research Centre and King's College London (and formerly of Richemont and a past INTA President) traced the origins of the concept of "sustainability" from 1962's Silent Spring by Rachel Carson to the present day. Speaking in his capacity as a Trustee of the Royal Academy of Culinary Arts, Frederick detailed the Academy's new "six pillars" of its food philosophy: sustainable; local; bio-friendly; animal-friendly; waste management; and communality. 90% of the chefs surveyed requested this initiative and, interestingly, the younger generations of chef are the most passionate about these issues (suggesting the trend towards sustainability will continue in future). Frederick has assisted the Academy in developing a mark to certify compliance with these pillars. Finally, Frederick reminded attendees that certifications can sometimes be misleading to consumers e.g. despite common assumptions, "organic" food products can include non-sustainable and unhealthy ingredients such as palm oil and corn syrup.
Katja Aßmann of Demeter-International explained the background and purpose of the Demeter mark, particularly familiar to German consumers for the certification of biodynamic products (i.e. more stringent than organic standards, and potentially valuable in reducing greenhouse gas (GHG) emissions). She noted that there is latent and increasing demand for "better" food and beverages: 80% of Germans do not want to consume GM products, and 41% would like to buy organic wherever possible.
Patricia Magaña-Spiegel of Fairtrade International spoke about the history of Fairtrade, its development of globally uniform standards of trade, and consumer recognition of the single worldwide Faitrade mark. In 2016, Fairtrade producers received an aggregate price premium of €150 million. However, Fairtrade's mission is now broader than fair prices, and the brand's strength is being leveraged in other areas e.g. elimination of forced and child labour.
Finally, Peter van Den Bulk (AB InBev) and Joseph J. Ferretti (PepsiCo, and current INTA President) spoke about the CSR programmes of their respective companies. Joe noted that, as large companies with a significant footprint, they feel even more responsible to reduce the negative side-effects of doing business. Peter detailed AB InBev's efforts to encourage more local supply (e.g. by brewing beer from Cassava root in Mozambique) and to reduce water consumption (from 2012 to 2016, consumption per litre produced has reduced from 3.54 to 3.14 litres, saving the equivalent of 40,000 Olympic swimming pools' worth of water per year, despite business growth)
Joe explained PepsiCo's goal to increase the sustainability and healthiness of its portfolio. The use of water was again a big issue, set against the backdrop of an expected 70% increase in global demand for food by 2050, and decreasing fresh water supplies. Joe suggested that, ultimately, achieving greater sustainability is also good for business: it allows continued supply of essential raw materials; if suppliers are paid fairly they are less likely to go bust and cause disruption; and reducing waste (only 6% of PepsiCo's production waste is sent to landfill) greatly helps the bottom line. Interestingly, PepsiCo retains a target of a 20% reduction in GHG emissions by 2030, notwithstanding the planned US withdrawal from the Paris climate accord.
The final session of the morning (moderated by Mette Andersen of Lego) was a two-part review of the standards brands must live up to in order to be deemed "responsible", and the trade mark issues in communicating this. Giulia Di Tommaso (Elipe), who works extensively with Unilever, took the first topic. Giulia gave an overview of the increasing standardised KPIs and rankings in this area, such as the OXFAM food brands ranking matrix, and the UN's sustainable development goals. Giulia noted that the latter features 169 KPIs i.e. the goals present considerable business complexity. However, Giulia argued that they also present an opportunity: there may be a significant first-mover advantage for businesses that take the lead on this. Consumers alone are unlikely explicitly to demand every possible improvement, but companies may benefit from (i) improved brand perception; and (ii) opening up new markets, along "build it and they will come" lines.
Laetitia Lagarde of Baker & McKenzie gave an overview of some trade mark issues arising for "green" businesses, products and services. In general, the bar for registration of marks featuring terms such as "eco" and "bio" is quite high given the inherently descriptive and/or laudatory character of the terms. Mette noted that the position is slightly different in Denmark - an inherently descriptive/non-distinctive mark will be registered with figurative elements - but in practice this will reduce likelihood of confusion in an infringement context (e.g. BIO BABY and BIO BABBY for nappies were held to not be confusingly similar). There are various other restrictions on use of "green" terms e.g. Regulation 834/2007 on the labelling of organic food products with the EU "leaf" logo, which treats the terms "bio", "eco" and "organic" as interchangeable (even though they may not be perceived as such by consumers). There also is a lesser-known mark available for non-edible environmentally-friendly goods and services, the EU Ecolabel (which has been around since 1994). The Cosmetics Regulation does not specify conditions for the use of "green" terms, so in this respect the cosmetics market is regulated by EU and national laws preventing misleading advertising. However, there are some private certification marks available e.g. the Soil Association mark in the UK, Ecocert in France and BDIH in Germany."
![]() |
IP Minister Jo Johnson proposes motion on UPC (Immunities and Privileges) Order 2017 |
"The British political headlines this week may have been dominated by the so-called “Brexit bill”, the Irish border conundrum and the curious case of the 58 Brexit impact assessments that may or may not ever have existed (never mind hard or soft Brexit; the impact assessment row suggests that the Government may have discovered Quantum Brexit). But to those of us with an interest in the UPC, the real political action this week took place not in Brussels or at the despatch box, but in the rather more rarefied surroundings of Committee Room 11 of the House of Commons, where, yesterday, the snappily-named Sixth Delegated Legislation Committee met to discuss the even more snappily-titled Unified Patent Court (Immunities and Privileges) Order 2017. [Do stay awake at the back of the class.]
Delegated Legislation Committee (DLC) debates are normally pretty dull affairs – DLCs have no power to amend a Statutory Instrument put before them, and can only vote on a motion that the Committee has “considered” the SI. However, the UPC Immunities and Privileges Order has acquired disproportionate significance, as it is the final piece of the legislative jigsaw which will allow the British Government to ratify the UPC Agreement. And so on Wednesday afternoon a small but dedicated band of UPC-watchers, including this Kat-for-a-day, headed along to Westminster to watch our lawmakers in action.
Jo Johnson MP, as the minister for IP, proposed the motion, relying on the by-now extremely well-worn refrains about the patent system being fragmented, costly and burdensome, implicitly suggesting that the UPC will solve all of this – a matter on which many have opinions… Mr Johnson did include one interesting statistic: about a quarter of all patents which are litigated in the UK are also litigated elsewhere in Europe between the same parties. If anybody has a source for this please let us know! [As we all know, it is rather a leap in logic to assume that all of those parties will want or need a single pan-European judgment, but we shan’t dwell on that here.]
More interesting to this observer were the comments made in reply by Opposition MPs. Jack Dromey MP noted the importance of Britain remaining a “nation of innovation” as it leaves the EU. He recognised the importance of the patent system in this regard. He called the legislation an “eminently sensible move” and stated that “we wholeheartedly support it”. That “we” is intriguing. Does this give us a clue to official Labour Party policy on the UPC? Or was he speaking only on behalf of those in attendance? Answers in the comments, please.
It was not all mutual congratulation though. Angela Eagle MP had some pertinent and uncomfortable questions for the Government about various of the elephants which were also crowded into the room besides MPs, clerks, Kats and other creatures. While calling the UPC a “wholly good thing”, Ms Eagle noted the irony of Britain assisting in bringing it into existence on the one hand while “fragmenting itself” from the EU on the other hand. In this respect she noted the fact that the UPC Agreement is not itself EU law, but that it is closely linked to the Unitary Patent Regulations. She also alluded to expert opinions that the UK would need to take “further steps” to stay in the UPC after Brexit – presumably here referring to the Gordon/Pascoe opinion and others. Ms Eagle further noted the recent developments in Germany and asked whether these would be a help or a hindrance to “getting the timing right” [this observer assumes that she prefers the option of the UPCA entering into force prior to Brexit]. She queried how the UK could remain part of the UPC system without remaining subject to the CJEU’s oversight, and rather pointedly asked Mr Johnson whether his department was prepared for the task of negotiating new agreements regarding the UK’s post-Brexit relationship to the UPC, if it was indeed the Government's intention to remain part of the UPC system.
Relevant though those points were, Ms Eagle unfortunately bundled them all into one rather rambling multi-question intervention which allowed Mr Johnson to respond in broad terms that didn’t shed much light on the Government’s future intentions. He stressed that, while still an EU member, the UK should and will carry out all necessary legislation allowing the Government to ratify the UPCA; he also stated an expectation that “we will need to negotiate with our European partners regarding the future relationship” but stopped short of saying whether or not the Government intended to seek any such relationship. [Only a cynic would suggest that the Government hasn’t thought about this yet.]
Mr Dromey noted that his support for the legislation was on the basis that there would be an “enduring mechanism” after Brexit and said that British exclusion from the UPC would be a source of “immense concern”. Mr Johnson’s words in reply were extremely carefully chosen – he simply noted that the Government wanted to put itself “in a position to enable the UPC to come into existence” and “continue to play a facilitating role in setting it up” but that the future relationship would be “subject to negotiation”. The CJEU issue was not mentioned at all.
After another intervention from Ms Eagle on similar lines as before, the Chair (Adrian Bailey MP) cut the debate short, noting that the discussion was supposed to be confined to the substance of the SI, and put the motion to a vote. The motion was carried unanimously, Mr Dromey’s “immense concern” notwithstanding.You can watch the proceedings here. The transcript in Hansard should be available sometime today.
So, what are we to make of all this?
First, and in practical terms: the DLC’s consideration of the SI means that all that remains in the Commons is a formality. A motion will be put before the House on behalf of Mr Johnson’s older brother, the Foreign Secretary, “That the draft Unified Patent Court (Immunities and Privileges) Order 2017, which was laid before this House on 26 June, be approved”. Indeed, such a motion has already been listed in the House of Commons’ Order of Business, although no date has yet been assigned. According to this helpful briefing paper, no debate will take place (the debate having been delegated to the DLC) and so the House can only approve or reject the SI. The last time an SI was rejected by the House of Commons was in 1978 and so it seems that approval is essentially a foregone conclusion.
The House of Lords must also give its approval to the SI in a similar fashion. The corresponding Grand Committee discussion in the House of Lords has been scheduled for 6 December.
If both the Commons and the Lords give their approval swiftly, there now seems to be a realistic possibility that the UK will be in a position to ratify the UPC Agreement before the year is out, or early in 2018 if the Commons and Lords votes cannot be scheduled in the remaining time before the Christmas recess.
Second, there is the rather more Rumsfeldian question of the “known unknowns”, chief among which is what Mr Johnson meant by wording such as “we want to put ourselves in a position” to enable the UPC to come into force, or “continue to play a facilitating role” or “work to bring it into operation”. The Eagle-eyed [pun fully intended] will notice that he has stopped short of saying that we will actually ratify the Agreement. Coupled with his acknowledgement that the future relationship will be a “matter for negotiation” does this give us a hint that the Government might withhold formal ratification as a bargaining chip subject to discussion of the future relationship (not unlike its, erm, wildly successful approach to negotiations over the Brexit bill, Irish border and future trade agreements)? Or is this GuestKat engaging in the type of meticulous verbal analysis against which Catnic warned us? Assuming that the official transcript in Hansard confirms this report, it’s possible to parse Mr Johnson’s words either as fulsome support for ratification or as a rather more noncommittal position. Truly, it seems, actions will speak louder than words over the next few months.
Another set of “known unknowns” is the Labour Party’s policy on the UPC. Mr Dromey’s comments seem to hint at Labour support for the UPC, and, indeed, support for continued UK membership after March 2019. But was he speaking on behalf of the party, or merely expressing a personal view? Enthusiasm for the UPC does not seem to sit comfortably with the party’s apparent commitment to leaving the single market and customs union, or the somewhat ambivalent stance of the current party leadership towards business.
Overall, then – progress has indisputably been made towards UK ratification, but whether the UK will actually ratify the Agreement, and what (if anything) it might seek in post-Brexit arrangements, remain as unclear as before. Of course, if the Bundesverfassungsgericht fails to issue a final judgment before 2019 or 2020 in the German constitutional case, this could all turn out to be rather academic. It will be most interesting to see what – if anything – emerges from Karlsruhe after the deadline for third-party submissions elapses on 31 December."
![]() |
Florence Foster Jenkins - the film |
![]() |
The actual Florence Foster Jenkins |
![]() |
the use of paws...a primary skill? |
![]() |
The use (any?) brush...a primary skill? |
![]() |
The AmeriKat sinking her teeth into some pretty inflexible FRAND royalties |
"closely monitor the SEP licensing markets with a particular focus on IoT technologies, by making use of the expert group that will be created and launching further studies if necessary. It will take stock of progress achieved and assess the need for further measures to ensure a balanced framework for smooth, efficient and effective licensing of SEPs on that basis."
“Today is a good day for consumers around the world, as well as the many businesses – small and large – that will rely on ‘fair reasonable and non-discriminatory’ access to the 5G open technology standard to create new products and services for the upcoming Internet of Things.” “IP Europe’s members welcome any initiative that will lead to smoother licensing negotiations. We note that this is particularly important for our SME members because they need as much support in the licensing process as the SME implementers.""And with that, all parties join hands with the Commission and march off into the sunset..." snarks Merpel....
![]() |
Kat-cloud |
* "Most Popular Intellectual Property Law Blawg" of all time according to Justia rankings (9 December 2015)
* Recommended by the European Patent Office as reading material for candidates for the European Qualifying Examinations 2013
* Listed as a "Top Legal Blog" in The Times Online, March 2011
* One of only two non-US weblogs listed in the 2010 ABA Journal Blawg 100
* Court Reporter Top Copyright Blog award winner, November 2010
* Number 1 in the 2010 Top Copyright Blog list compiled by the Copyright Litigation Blog, July 2010
* Selected by United States Library of Congress for inclusion in its historic collections of Internet materials related to Legal Blawgs 2010
* Top Patent Blog poll 2009: 3rd out of 50 in the "Favourite Patent Blog" poll and 2nd out of 50 in the "Most-read" poll
* ComputerWeekly IT Law and Governance Blog of the Year 20 August 2008
* Best of the Blogs, Times Online, 21 August 2008
* Listed as one of Managing Intellectual Property magazine's Fifty Most Influential People of 2005, 2011, 2013 and 2014